New and innovative immunotherapy medicines developed by America’s biopharmaceutical research companies are transforming how we fight cancer and are providing newfound hope to patients.
Rather than killing cancer cells directly with traditional tools like radiation or chemotherapy, immunotherapy seeks to harness the immune system’s power to eliminate the cancer or slow its growth and ability to spread. Research shows immunotherapy is improving outcomes and survival rates for some patients, including kidney and lung cancer. In fact, the American Association for Cancer Research just released new research showing that for advanced-melanoma patients, survival rates are improving thanks in part to these new treatment options.
Biopharmaceutical researchers are urgently working to gain new insights into the complex interactions between patients’ immune systems and the cancer cells growing in their bodies with the goal of markedly improving outcomes in many more tumor types. With 836 medicines and vaccines in development for cancer, 80 percent of which have the potential to be first-in-class treatments, millions of Americans living with cancer have hope for a brighter future.
Stakeholders throughout the health care ecosystem are in agreement that new immunotherapy medicines are providing tremendous value to cancer patients in need. See what they are saying below:
Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.